-
公开(公告)号：US20070020336A1
公开(公告)日：2007-01-25
申请号：US11489466
申请日：2006-07-20
IPC分类号： A61K38/13 , A61K38/39 , A61K31/724 , A61K31/717 , A61K31/573 , A61K31/5513 , A61K31/557 , A61K31/19 , A61K9/14
CPC分类号： A61K47/48969 , A61K9/0043 , A61K9/0048 , A61K9/10 , A61K31/404 , A61K31/42 , A61K31/5377 , A61K31/5513 , A61K31/565 , A61K31/573 , A61K31/58 , A61K38/13 , A61K47/6905 , A61K47/6951 , B82Y5/00 , Y10S514/914
摘要： The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 10% (w/v) to about 99.9% (w/v) of the drug as solid drug/cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist. Further, the invention provides a method for treating a condition of the posterior segment and/or anterior segment of the eye comprising applying to the eye surface, in an amount which delivers to said segment or segments a therapeutically effective amount of a drug suitable for treating said condition, an ophthalmic composition which is as defined above. Nasal compositions and methods and ophthalmic and nasal compositions in powder form are also provided.
摘要翻译： 本发明提供了一种眼用组合物，其为包含药物，环糊精和水的水性悬浮液，所述组合物的水相为溶液中约0.1％（w / v）至约90％（w / v） 溶解的药物和溶解的药物/环糊精复合物，以及作为固体药物/环糊精颗粒的约10％（w / v）至约99.9％（w / v）的药物的固相，悬浮于 水相; 固体颗粒的尺寸为约10nm至约1mm，药物/环糊精颗粒能够在施用于眼表面后24小时内溶解于水性泪液中。 水性眼睛悬浮液可以是滴眼液，眼凝胶或眼睛雾沫的形式。 此外，本发明提供了一种用于治疗眼部后段和/或前段的病症的方法，包括向眼表面施用一定量的量，其量递送至所述片段或分段治疗有效量的适于治疗的药物 所述病症，如上所述的眼用组合物。 还提供鼻组合物和方法以及粉末形式的眼和鼻组合物。
-
公开(公告)号：US08372425B2
公开(公告)日：2013-02-12
申请号：US12609845
申请日：2009-10-30
CPC分类号： A61K31/202 , A61K31/20 , A61K31/201
摘要： The invention relates to fatty acid stimulation of rectal mucosa initiating the process of defecation, acting as a laxative. Furthermore, the invention relates to the usage of free fatty acids, fatty acid mixtures and fatty acid extracts from marine lipids in pharmaceutical formulations such as suppositories, ointments, tablets and gelatin capsules for treatment and prevention of multiple disorders like constipation, hemorrhoids, bacterial infections (e.g. helicobacter pylori), viral infections (e.g. herpes simplex virus infections) and inflammations, as well as against fissura ani and pruritus ani.
-
3.发明申请CYCLODEXTRIN NANOTECHNOLOGY FOR OPHTHALMIC DRUG DELIVERY 审中-公开CYCLODEXTRIN NANOTECHNOLOGY OPHTHALMIC DRUG DELIVERY公开(公告)号：US20120028944A1
公开(公告)日：2012-02-02
申请号：US13014964
申请日：2011-01-27
IPC分类号： A61K31/573 , A61K31/403 , A61K38/13 , A61K31/565 , A61P31/12 , A61K31/42 , A61K31/58 , A61P27/02 , A61P29/00 , A61P31/04 , A61K31/506 , A61K31/5513
CPC分类号： A61K31/5377 , A61K9/0043 , A61K9/0048 , A61K9/10 , A61K31/404 , A61K31/42 , A61K31/5513 , A61K31/565 , A61K31/573 , A61K31/58 , A61K38/13 , A61K47/6905 , A61K47/6951 , B82Y5/00 , Y10S514/914
摘要： The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 10% (w/v) to about 99.9% (w/v) of the drug as solid drug/cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist. Further, the invention provides a method for treating a condition of the posterior segment and/or anterior segment of the eye comprising applying to the eye surface, in an amount which delivers to said segment or segments a therapeutically effective amount of a drug suitable for treating said condition, an ophthalmic composition which is as defined above. Nasal compositions and methods and ophthalmic and nasal compositions in powder form are also provided.
摘要翻译： 本发明提供了一种眼用组合物，其为包含药物，环糊精和水的水性悬浮液，所述组合物的水相为溶液中约0.1％（w / v）至约90％（w / v） 溶解的药物和溶解的药物/环糊精复合物，以及作为固体药物/环糊精颗粒的约10％（w / v）至约99.9％（w / v）的药物的固相，悬浮于 水相; 固体颗粒的尺寸为约10nm至约1mm，药物/环糊精颗粒能够在施用于眼表面后24小时内溶解于水性泪液中。 水性眼睛悬浮液可以是滴眼液，眼凝胶或眼睛雾沫的形式。 此外，本发明提供了一种用于治疗眼部后段和/或前段的病症的方法，包括向眼表面施用一定量的量，其量递送至所述片段或分段治疗有效量的适于治疗的药物 所述病症，如上所述的眼用组合物。 还提供鼻组合物和方法以及粉末形式的眼和鼻组合物。
-
公开(公告)号：US08633172B2
公开(公告)日：2014-01-21
申请号：US13758955
申请日：2013-02-04
IPC分类号： A61K31/724 , A61K31/715
CPC分类号： A61K47/48969 , A61K9/0043 , A61K9/0048 , A61K9/10 , A61K31/404 , A61K31/42 , A61K31/5377 , A61K31/5513 , A61K31/565 , A61K31/573 , A61K31/58 , A61K38/13 , A61K47/6905 , A61K47/6951 , B82Y5/00 , Y10S514/914
摘要： The invention provides an ophthalmic composition which is an aqueous suspension comprising drug, cyclodextrin and water, the composition having an aqueous phase of from about 0.1% (w/v) to about 90% (w/v) of the drug in solution, as dissolved free drug and as dissolved drug/cyclodextrin complex(es), and a solid phase of from about 10% (w/v) to about 99.9% (w/v) of the drug as solid drug/cyclodextrin particles, suspended in the aqueous phase; the size of the solid particles being from about 10 nm to about 1 mm, the drug/cyclodextrin particles being capable of dissolving in aqueous tear fluid within 24 hours of application to the eye surface. The aqueous eye suspension can be in the form of eye drops, eye gel or eye mist. Further, the invention provides a method for treating a condition of the posterior segment and/or anterior segment of the eye comprising applying to the eye surface, in an amount which delivers to said segment or segments a therapeutically effective amount of a drug suitable for treating said condition, an ophthalmic composition which is as defined above. Nasal compositions and methods and ophthalmic and nasal compositions in powder form are also provided.
摘要翻译： 本发明提供了一种眼用组合物，其为包含药物，环糊精和水的水性悬浮液，所述组合物的水相为溶液中约0.1％（w / v）至约90％（w / v） 溶解的药物和溶解的药物/环糊精复合物，以及作为固体药物/环糊精颗粒的约10％（w / v）至约99.9％（w / v）的药物的固相，悬浮于 水相; 固体颗粒的尺寸为约10nm至约1mm，药物/环糊精颗粒能够在施用于眼表面后24小时内溶解于水性泪液中。 水性眼睛悬浮液可以是滴眼液，眼凝胶或眼睛雾沫的形式。 此外，本发明提供了一种用于治疗眼部后段和/或前段的病症的方法，包括向眼表面施用一定量的量，其量递送至所述片段或分段治疗有效量的适于治疗的药物 所述病症，如上所述的眼用组合物。 还提供鼻组合物和方法以及粉末形式的眼和鼻组合物。
-
公开(公告)号：US20100113387A1
公开(公告)日：2010-05-06
申请号：US12609845
申请日：2009-10-30
IPC分类号： A61K31/724 , A61K31/22 , A61K31/19 , A61K31/20 , A61K31/201 , A61P1/00 , A61K31/202 , A61P31/22
CPC分类号： A61K31/202 , A61K31/20 , A61K31/201
摘要： The invention relates to fatty acid stimulation of rectal mucosa initiating the process of defecation, acting as a laxative. Furthermore, the invention relates to the usage of free fatty acids, fatty acid mixtures and fatty acid extracts from marine lipids in pharmaceutical formulations such as suppositories, ointments, tablets and gelatin capsules for treatment and prevention of multiple disorders like constipation, hemorrhoids, bacterial infections (e.g. helicobacter pylori), viral infections (e.g. herpes simplex virus infections) and inflammations, as well as against fissura ani and pruritus ani.
摘要翻译： 本发明涉及直肠粘膜的脂肪酸刺激，引发排便过程，作为泻药。 此外，本发明涉及在诸如栓剂，软膏剂，片剂和明胶胶囊的药物制剂中来自海洋脂质的游离脂肪酸，脂肪酸混合物和脂肪酸提取物的用途，用于治疗和预防诸如便秘，痔疮，细菌感染 （例如幽门螺杆菌），病毒感染（例如单纯疱疹病毒感染）和炎症，以及针对烟草和瘙痒症。
-
公开(公告)号：US06699849B1
公开(公告)日：2004-03-02
申请号：US09250185
申请日：1999-02-16
IPC分类号： A61K31715
CPC分类号： B82Y5/00 , A61K47/6951 , C08B37/0015
摘要： Methods for enhancing the complexation efficiency of a drug with cyclodextrin and for enhancing the availability of a drug following administration of a cyclodextrin-drug complex.
摘要翻译： 用环糊精提高药物复合效率的方法，以及在施用环糊精 - 药物复合物后增强药物的可利用性。
-
公开(公告)号：US07774036B2
公开(公告)日：2010-08-10
申请号：US11146278
申请日：2005-06-07
申请人： Gisli Hreinn Halldorsson , Einar Stefansson , Jon Atli Benediktsson , Robert Arnar Karlsson , Sveinn Hakon Hardarson , Thor Eysteinsson , James M. Beach
发明人： Gisli Hreinn Halldorsson , Einar Stefansson , Jon Atli Benediktsson , Robert Arnar Karlsson , Sveinn Hakon Hardarson , Thor Eysteinsson , James M. Beach
IPC分类号： A61B5/1455
CPC分类号： A61B3/1241 , A61B5/14555 , A61B5/7264
摘要： The example embodiments relate to a system for automatically evaluating oxygen saturation of the optic nerve and retina, including an image capturing system which includes a fundus camera, a four wavelengths beam splitter, a digital image capturing device, a computer system, and image processing software for registering and analyzing multi-spectral images of the retina, and for evaluating oxygen saturation level.
摘要翻译： 示例性实施例涉及用于自动评估视神经和视网膜的氧饱和度的系统，包括包括眼底照相机，四波长分束器，数字图像捕获装置，计算机系统和图像处理软件的图像捕获系统 用于登记和分析视网膜的多光谱图像，并用于评估氧饱和度水平。
-
公开(公告)号：US20060276698A1
公开(公告)日：2006-12-07
申请号：US11146278
申请日：2005-06-07
申请人： Gisli Halldorsson , Einar Stefansson , Jon Benediktsson , Robert Karlsson , Sveinn Hardarson , Thor Eysteinsson , James Beach
发明人： Gisli Halldorsson , Einar Stefansson , Jon Benediktsson , Robert Karlsson , Sveinn Hardarson , Thor Eysteinsson , James Beach
IPC分类号： A61B5/00
CPC分类号： A61B3/1241 , A61B5/14555 , A61B5/7264
摘要： The present invention relates to a system for automatically evaluating oxygen saturation of the optic nerve and retina, said system comprising: image capturing system further comprising: a fundus camera (26), a four wavelengths beam splitter (27), a digital image capturing device (28), a computer system, image processing software performing in real-time the steps of: registering set of multi-spectral images (1) by, binarizing the multi-spectral image (7), find the all the border regions of each image by finding the region including the straight line that passes the most number of points in the region (8), use the orientation of the borders to evaluate the orientation of each spectral image (9), equalize the orientation of each spectral image by rotating the spectral image (10), edge detect each spectral image (11), estimate the translation between the spectral images based on the edges of adjacent images (12), transform the images to a stack of registered images (13), locating blood vessels (2) in each of the multi-spectral images by, retrieving registered spectral images (14), for each spectral image, remove defective pixels (15), enhance image contrast (16), perform top-hat transform using structuring element larger than the largest vessel diameter (17), binarize each image (18), apply filter for smoothing the image (19), combine all the spectral images using binary AND operator (20), skeletonize the resulting image (21), prune the skeleton image (22), re-grow the pruned image (23), locate junction points (24), evaluating the width of the blood vessels (3) by calculating the normal vector to the vessel direction to, estimate the direction and position of the vessel profile, evaluate positions of vessel walls based on the vessel profile obtained, evaluate vessel width based on the position of the vessel walls, selecting samples for calculating optical density, calculating the optical density ratio (4), evaluating oxygen saturation level (5), and presenting the results (6), wherein presenting the results may include presenting numerical and visual representation of the oxygen saturation.
-
公开(公告)号：US09579052B2
公开(公告)日：2017-02-28
申请号：US13377749
申请日：2010-06-11
IPC分类号： G06K9/00 , A61B5/1455 , A61B5/145 , A61B5/00
CPC分类号： A61B5/14555 , A61B5/14535 , A61B5/726
摘要： A method and an apparatus for detecting change in retinal oxygen saturation over time are provided. The method includes the steps of capturing a first group of images of two or more wavelengths, calculating oxygen saturation of a vessel in the first group of images, storing the first group of images on a data storage device, capturing a second group of images of two or more wavelengths, calculating the oxygen saturation of a vessels in the second group of images, storing the second group of images on a data storage device, spatially registering the pair of the group of images, captured at different time and calculate the change in oxygen saturation. The method also includes means to validate whether an observed change in oxygen saturation is a real physiological change or artificial.
摘要翻译： 提供了一种随时间检测视网膜血氧饱和度变化的方法和装置。 该方法包括以下步骤：捕获第一组两个或更多波长的图像，计算第一组图像中的血管的氧饱和度，将第一组图像存储在数据存储设备上，捕获第二组图像 两个或更多个波长，计算第二组图像中的血管的氧饱和度，将第二组图像存储在数据存储装置上，在空间上记录在不同时间捕获的一组图像，并计算 氧饱和度。 该方法还包括验证观察到的氧饱和度变化是真正的生理变化还是人为的手段。
-
公开(公告)号：US20120179486A1
公开(公告)日：2012-07-12
申请号：US13380777
申请日：2010-06-25
申请人： Einar Stefansson , Toke Bek , Olafur Palsson , Stefan Einarsson , Anna Bryndis Einarsdottir , Anna Gudmunsdottir , Thor Aspelund
发明人： Einar Stefansson , Toke Bek , Olafur Palsson , Stefan Einarsson , Anna Bryndis Einarsdottir , Anna Gudmunsdottir , Thor Aspelund
IPC分类号： G06Q50/22
摘要： The present invention discloses methods, computer program and system to overcome the limitation of the current clinical practice. This is achieved by using information technology and the vast amount of epidemiological data available to create algorithms that calculate the risk or severity profile of an individual with any given disease. The individual profile presents the current condition and/or position of the individual in comparison with the mean base curve of the total population and in accordance with upper and lower risk limits. The individual profile is then fitted with its optimal use of healthcare resources, such as medication, surgery, laser treatment, surveillance and follow-up, to optimize and individualize the health outcome of this individual, and at the same time optimize and individualize the allocation of healthcare resources within the system.
摘要翻译： 本发明公开了克服当前临床实践限制的方法，计算机程序和系统。 这是通过使用信息技术和大量可用的流行病学数据来创建计算任何给定疾病的个体的风险或严重程度的算法来实现的。 个人资料显示了与总人口的平均基线曲线相比较，并根据上下风险限制，个人的现状和/或位置。 然后，个人资料适合使用医疗资源，如药物治疗，手术，激光治疗，监测和随访，优化和个性化个体健康结果，同时优化和个性化分配 的系统内的医疗资源。
-
-
-
-
-
-
-
-
-
搜索结果
10 条记录 (耗时 0.016 秒)
